Régions d'ancrage à la matrice nucléaire : Questions médicales fréquentes
Nom anglais: Matrix Attachment Regions
Descriptor UI:D045170
Tree Number:G05.360.080.534
Termes MeSH sélectionnés :
Network Meta-Analysis
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Régions d'ancrage à la matrice nucléaire : Questions médicales les plus fréquentes",
"headline": "Régions d'ancrage à la matrice nucléaire : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Régions d'ancrage à la matrice nucléaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-10",
"dateModified": "2025-04-06",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Régions d'ancrage à la matrice nucléaire"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Structures génétiques",
"url": "https://questionsmedicales.fr/mesh/D040342",
"about": {
"@type": "MedicalCondition",
"name": "Structures génétiques",
"code": {
"@type": "MedicalCode",
"code": "D040342",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Régions d'ancrage à la matrice nucléaire",
"alternateName": "Matrix Attachment Regions",
"code": {
"@type": "MedicalCode",
"code": "D045170",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Tian-Yun Wang",
"url": "https://questionsmedicales.fr/author/Tian-Yun%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China."
}
},
{
"@type": "Person",
"name": "Xiao-Yin Wang",
"url": "https://questionsmedicales.fr/author/Xiao-Yin%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China."
}
},
{
"@type": "Person",
"name": "Yan-Long Jia",
"url": "https://questionsmedicales.fr/author/Yan-Long%20Jia",
"affiliation": {
"@type": "Organization",
"name": "Pharmacy Collage, Xinxiang Medical University, Xinxiang 453003, Henan, China."
}
},
{
"@type": "Person",
"name": "Xiao Guo",
"url": "https://questionsmedicales.fr/author/Xiao%20Guo",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Xinxiang 453003, Henan, China; International Joint Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang 453003, Henan, China."
}
},
{
"@type": "Person",
"name": "Lubna Anis",
"url": "https://questionsmedicales.fr/author/Lubna%20Anis",
"affiliation": {
"@type": "Organization",
"name": "Owerko Centre for Children's Neurodevelopment and Mental Health, Alberta Children's Hospital Research Institute, Faculty of Nursing, University of Calgary, Calgary, AB T2N 1N4, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Kenward-Roger-type corrections for inference methods of network meta-analysis and meta-regression.",
"datePublished": "2023-07-03",
"url": "https://questionsmedicales.fr/article/37399845",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jrsm.1652"
}
},
{
"@type": "ScholarlyArticle",
"name": "Diagnostic yield and safety of diagnostic techniques for pulmonary lesions: systematic review, meta-analysis and network meta-analysis.",
"datePublished": "2024-09-18",
"url": "https://questionsmedicales.fr/article/39293856",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1183/16000617.0046-2024"
}
},
{
"@type": "ScholarlyArticle",
"name": "Topical anti-inflammatory treatments for eczema: network meta-analysis.",
"datePublished": "2024-08-06",
"url": "https://questionsmedicales.fr/article/39105474",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD015064.pub2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Systemic corticosteroids for the prevention of bronchopulmonary dysplasia, a network meta-analysis.",
"datePublished": "2023-08-31",
"url": "https://questionsmedicales.fr/article/37650547",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD013730.pub2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Percutaneous coronary intervention in calcified stenoses: a protocol for a systematic review with meta-analysis, trial sequential analysis and network meta-analysis.",
"datePublished": "2022-09-02",
"url": "https://questionsmedicales.fr/article/36691161",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bmjopen-2022-063884"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures génétiques",
"item": "https://questionsmedicales.fr/mesh/D040342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Régions d'ancrage à la matrice nucléaire",
"item": "https://questionsmedicales.fr/mesh/D045170"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Régions d'ancrage à la matrice nucléaire - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Régions d'ancrage à la matrice nucléaire",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Régions d'ancrage à la matrice nucléaire",
"description": "Comment identifier les MAR dans le génome ?\nQuels tests sont utilisés pour étudier les MAR ?\nLes MAR sont-elles visibles par microscopie ?\nPeut-on détecter des mutations dans les MAR ?\nLes MAR sont-elles associées à des maladies ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Network+Meta-Analysis&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Régions d'ancrage à la matrice nucléaire",
"description": "Quels symptômes sont liés aux anomalies des MAR ?\nLes MAR affectent-elles l'expression génique ?\nY a-t-il des symptômes associés aux cancers liés aux MAR ?\nLes MAR influencent-elles le développement embryonnaire ?\nLes anomalies des MAR peuvent-elles causer des troubles ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Network+Meta-Analysis&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Régions d'ancrage à la matrice nucléaire",
"description": "Peut-on prévenir les anomalies des MAR ?\nY a-t-il des tests de dépistage pour les anomalies des MAR ?\nComment réduire le risque de cancers liés aux MAR ?\nL'alimentation influence-t-elle les MAR ?\nLes examens médicaux réguliers aident-ils ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Network+Meta-Analysis&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Régions d'ancrage à la matrice nucléaire",
"description": "Y a-t-il des traitements ciblant les MAR ?\nComment les thérapies géniques affectent-elles les MAR ?\nLes traitements du cancer affectent-ils les MAR ?\nPeut-on utiliser des médicaments pour moduler les MAR ?\nLes interventions chirurgicales peuvent-elles affecter les MAR ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Network+Meta-Analysis&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Régions d'ancrage à la matrice nucléaire",
"description": "Quelles complications peuvent survenir avec des anomalies des MAR ?\nLes anomalies des MAR peuvent-elles entraîner des maladies chroniques ?\nY a-t-il des complications liées aux traitements des MAR ?\nLes complications sont-elles réversibles ?\nLes anomalies des MAR affectent-elles la fertilité ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Network+Meta-Analysis&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Régions d'ancrage à la matrice nucléaire",
"description": "Quels sont les facteurs de risque pour les anomalies des MAR ?\nL'âge influence-t-il les anomalies des MAR ?\nLe mode de vie affecte-t-il les MAR ?\nLes antécédents familiaux jouent-ils un rôle ?\nLes agents environnementaux influencent-ils les MAR ?",
"url": "https://questionsmedicales.fr/mesh/D045170?mesh_terms=Network+Meta-Analysis&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les MAR dans le génome ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les MAR peuvent être identifiées par des techniques de séquençage et d'analyse bioinformatique."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour étudier les MAR ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests comme la PCR et l'hybridation in situ sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les MAR sont-elles visibles par microscopie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les MAR ne sont pas directement visibles, mais leur effet sur la structure peut l'être."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des mutations dans les MAR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations dans les MAR peuvent être détectées par séquençage ciblé."
}
},
{
"@type": "Question",
"name": "Les MAR sont-elles associées à des maladies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines MAR peuvent être liées à des maladies génétiques ou à des cancers."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux anomalies des MAR ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anomalies des MAR peuvent entraîner des dysfonctionnements cellulaires, mais pas de symptômes spécifiques."
}
},
{
"@type": "Question",
"name": "Les MAR affectent-elles l'expression génique ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les MAR jouent un rôle crucial dans la régulation de l'expression génique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes associés aux cancers liés aux MAR ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes dépendent du type de cancer, mais peuvent inclure fatigue, douleur, et perte de poids."
}
},
{
"@type": "Question",
"name": "Les MAR influencent-elles le développement embryonnaire ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les MAR sont impliquées dans la régulation des gènes essentiels au développement embryonnaire."
}
},
{
"@type": "Question",
"name": "Les anomalies des MAR peuvent-elles causer des troubles ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies peuvent contribuer à des troubles du développement ou des cancers."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies des MAR ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un mode de vie sain peut réduire les risques de maladies associées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests de dépistage pour les anomalies des MAR ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de tests de dépistage spécifiques pour les anomalies des MAR."
}
},
{
"@type": "Question",
"name": "Comment réduire le risque de cancers liés aux MAR ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les facteurs de risque connus comme le tabagisme et l'exposition à des agents cancérigènes."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle les MAR ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut influencer l'expression génique, y compris celle des MAR."
}
},
{
"@type": "Question",
"name": "Les examens médicaux réguliers aident-ils ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers peuvent aider à détecter précocement des maladies associées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements ciblant les MAR ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de traitements spécifiques ciblant les MAR."
}
},
{
"@type": "Question",
"name": "Comment les thérapies géniques affectent-elles les MAR ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les thérapies géniques peuvent modifier l'expression des gènes associés aux MAR."
}
},
{
"@type": "Question",
"name": "Les traitements du cancer affectent-ils les MAR ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements du cancer peuvent influencer l'activité des MAR."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des médicaments pour moduler les MAR ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours pour développer des médicaments modulant l'activité des MAR."
}
},
{
"@type": "Question",
"name": "Les interventions chirurgicales peuvent-elles affecter les MAR ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Indirectement, en modifiant l'environnement cellulaire, mais pas directement les MAR."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des anomalies des MAR ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles du développement et un risque accru de cancers."
}
},
{
"@type": "Question",
"name": "Les anomalies des MAR peuvent-elles entraîner des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines anomalies peuvent contribuer à des maladies chroniques comme le cancer."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications liées aux traitements des MAR ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent avoir des effets secondaires, mais pas spécifiquement liés aux MAR."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Les anomalies des MAR affectent-elles la fertilité ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines anomalies peuvent influencer la fertilité, mais cela dépend du contexte génétique."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les anomalies des MAR ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des prédispositions génétiques et des expositions environnementales."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les anomalies des MAR ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge avancé peut augmenter le risque de mutations génétiques, y compris dans les MAR."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il les MAR ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme le tabagisme et l'alimentation peuvent influencer les MAR."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies génétiques peuvent augmenter le risque d'anomalies."
}
},
{
"@type": "Question",
"name": "Les agents environnementaux influencent-ils les MAR ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des agents cancérigènes peut affecter l'intégrité des MAR."
}
}
]
}
]
}
Network meta-analysis has been an essential methodology of systematic reviews for comparative effectiveness research. The restricted maximum likelihood (REML) method is one of the current standard inf...
With recent advancements in bronchoscopic procedures, data on the best modality to sample peripheral pulmonary lesions (PPLs) is lacking, especially comparing bronchoscopy with computed tomography-gui...
We performed a meta-analysis, pairwise meta-analysis and network meta-analysis on studies reporting diagnostic yield and complications with the use of CT-TBNA, radial endobronchial ultrasound (rEBUS),...
We included 363 studies. The overall pooled diagnostic yield was 78.1%, the highest with CT-TBNA (88.9%), followed by RAB (84.8%) and the least with rEBUS (72%). In the pairwise meta-analysis, only rE...
Although CT-TBNA is the most effective approach to sample PPLs, RAB has a comparable diagnostic yield with a lesser complication rate. Further prospective studies are needed comparing CT-TBNA and RAB....
Eczema (atopic dermatitis) is the most burdensome skin condition worldwide and cannot currently be prevented or cured. Topical anti-inflammatory treatments are used to control eczema symptoms, but the...
To compare and rank the efficacy and safety of topical anti-inflammatory treatments for people with eczema using a network meta-analysis....
We searched the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and trial registries on 29 June 2023, and checked the reference lists of included studies....
We included within-participant or between-participant randomised controlled trials (RCTs) in people of any age with eczema of any severity, but excluded trials in clinically infected eczema, seborrhoe...
We used standard Cochrane methods. Primary outcomes were patient-reported eczema symptoms, clinician-reported eczema signs and investigator global assessment. Secondary outcomes were health-related qu...
We included 291 studies involving 45,846 participants with the full spectrum of eczema severity, mainly conducted in high-income countries in secondary care settings. Most studies included adults, wit...
Potent TCS, JAK inhibitors and tacrolimus 0.1% were consistently ranked as amongst the most effective topical anti-inflammatory treatments for eczema and PDE-4 inhibitors as amongst the least effectiv...
Despite considerable improvement in outcomes for preterm infants, rates of bronchopulmonary dysplasia (BPD) remain high, affecting an estimated 33% of very low birthweight infants, with corresponding ...
To determine whether differences in efficacy and safety exist between high-dose dexamethasone, moderate-dose dexamethasone, low-dose dexamethasone, hydrocortisone, and placebo in the prevention of BPD...
We searched the Cochrane Library for all systematic reviews of systemic corticosteroids for the prevention of BPD and searched for completed and ongoing studies in the following databases in January 2...
We included randomized controlled trials (RCTs) in preterm infants (< 37 weeks' gestation) at risk for BPD that evaluated systemic corticosteroids (high-dose [≥ 4 mg/kg cumulative dose] dexamethasone,...
Our main information sources were the systematic reviews, with reference to the original manuscript only for data not included in these reviews. Teams of two paired review authors independently perfor...
We included 59 studies, involving 6441 infants, in our analyses. Only six of the included studies provided direct comparisons between any of the treatment (dexamethasone or hydrocortisone) groups, for...
Low-dose dexamethasone increased the risk for cerebral palsy (RR 1.92, 95% CI 1.12 to 3.28; moderate-certainty evidence) compared with control. Hydrocortisone may decrease the risk of major neurosenso...
No effect was observed for the outcomes of major neurosensory disability or cerebral palsy. The evidence for the primary outcomes was of overall low certainty, with notable deductions for imprecision ...
While early treatment with moderate-dose dexamethasone or late treatment with high-dose dexamethasone may lead to the best effects for survival without BPD, the certainty of the evidence is low. There...
Severely calcified coronary stenoses are difficult to treat with percutaneous coronary interventions. The presence of severe calcifications complicates lesion preparation, advancement of stents and ac...
We will conduct a systematic review of randomised trials enrolling patients with calcified coronary artery disease undergoing percutaneous coronary intervention. We will investigate any percutaneous t...
No ethics approval is required for this study. The results will be published in a peer-reviewed journal in this field....
CRD42021226034....
Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects mainly young adults (two to three times more frequently in women than in men) and causes significant disability ...
To compare adverse effects of immunotherapies for people with MS or clinically isolated syndrome (CIS), and to rank these treatments according to their relative risks of adverse effects through networ...
We searched CENTRAL, PubMed, Embase, two other databases and trials registers up to March 2022, together with reference checking and citation searching to identify additional studies....
We included participants 18 years of age or older with a diagnosis of MS or CIS, according to any accepted diagnostic criteria, who were included in randomized controlled trials (RCTs) that examined o...
We used standard Cochrane methods for data extraction and pairwise meta-analyses. For NMAs, we used the netmeta suite of commands in R to fit random-effects NMAs assuming a common between-study varian...
This NMA included 123 trials with 57,682 participants...
We found mostly low and very low-certainty evidence that drugs used to treat MS may not increase SAEs, but may increase withdrawals compared with placebo. The results suggest that there is no importan...
A comprehensive network meta-analysis comparing the effects of individual sodium-glucose cotransporter 2 (SGLT2) inhibitors on patients with and without comorbidities including diabetes mellitus (DM),...
We searched PubMed, Embase, Cochrane, and ClinicalTrials.gov for randomized controlled trials up to March 28, 2023. Network meta-analysis using a random-effects model was conducted to calculate risk r...
A total of fourteen trials with 75,334 patients were analyzed. Among these, 40,956 had taken SGLT2 inhibitors and 34,378 had not. One of the main results with particular findings was empagliflozin use...
Our network meta-analysis revealed that empagliflozin users with diabetes experienced a lower risk of dying from any cause than those using dapagliflozin. Additionally, canagliflozin users demonstrate...
PROSPERO [CRD42022361906]....
Multiple randomized controlled trials, each comparing a subset of competing interventions, can be synthesized by means of a network meta-analysis to estimate relative treatment effects between all int...
Surgical treatment of complete rectal prolapse can be undertaken via an abdominal or a perineal approach. The present network meta-analysis aimed to compare the outcomes of different abdominal and per...
A PRISMA-compliant systematic review of PubMed, Scopus, and Web of Science was conducted. Randomized clinical trials comparing two or more procedures for the treatment of complete rectal prolapse were...
Nine randomized controlled trials with 728 patients were included. The follow-up ranged between 12 and 47 months. Posterior mesh rectopexy had significantly lower odds of recurrence than did the Altem...
Posterior mesh rectopexy ranked best with the lowest recurrence while perineal procedures ranked worst with the highest recurrence rates....
Several vaccines showed a good safety profile and significant efficacy against COVID-19. Moreover, in the absence of direct head to head comparison between COVID-19 vaccines, a network meta-analysis t...
Databases PubMed, CENTRAL, medRxiv, and clinicaltrials.gov were searched. Studies were included if they were placebo-controlled clinical trials and reported the safety profile and/or effectiveness of ...
Forty-nine clinical trials that included 421,173 participants and assessed 28 vaccines were included in this network meta-analysis. The network meta-analysis showed that Pfizer is the most effective i...
We found that almost all of the vaccines included in this study crossed the threshold of 50% efficacy. However, some of them did not reach the previously mentioned threshold against the B.1.351 varian...
